Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
12Jan2026
  • Home
  • About
  • News
  • Subscribe
12Jan2026
Cost Curve NewsCost Curve News
Cost Curve News

The Wait for 340B Rebate Model Guidance from the Government Just Got Longer

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

Reading on 340B … While Waiting on 340B

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

The Government Could Upend 340B Next Week. Here Are Three Ways That Could Go Down

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

Companies Have a Unique Opportunity to Seize the MFN Narrative. Here Are Seven Ways to Do That

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

A Must-Read Assessment of 340B Legislation Encourages Policymakers to Think Hard About ‘Tradeoffs’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

APEX | The Current State of Play on MFN: Skepticism on Administrative Execution, Attention Around Congressional Action

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

The Government and Companies Are Both Preparing for the (As Yet Unannounced) Pharma Tariffs

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

APEX | A New Reuters Analysis of 2024 Launch Prices Doesn’t Say What Reuters Thinks It Does

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

The CBO Drops Numbers on What the Reconciliation Bill Will Cost (and Save), With Insight on Orphans, PBMs, and Pharmacies

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

Breaking News on MFN ‘Targets’ … and a Review of the Right’s Reaction to the Policy

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
141516

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

January 7, 2026

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

January 6, 2026

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

January 5, 2026

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (3,074)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,265)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (2,015)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,824)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,816)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2026 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe